The SNPs used in these analyses are not ideal instruments for single IGF peptides: several that affect IGF1 also appear to alter IGFBP3 concentrations and vice versa, and perhaps also influence circulating IGF2 (for which we did not find suitable variants to instrument specifically).37 Therefore, variants are not indicating AD risk differences attributable to one IGF molecule specifically, although sensitivity analyses using subsets of SNPs that were carefully assessed for magnitudes of effects on each peptide can help in this respect. The gene discussed is IGF2; the disease is Alzheimer disease.